Mirvetuximab Soravtansine in the Treatment of Chemotherapy-Resistant Ovarian Cancer: A Systematic Review.

Int J Mol Sci · 2026 · PMC13361919 · PMID 42450158

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

did not reach statistical significancep = 0.063so close (0.05 < p ≤ 0.1)

In the high FRα expression population, a trend toward benefit was observed for the MIRV group with a median of 4.8 months and the CTH group with a median of 3.3 months (HR 0.69), but this did not reach statistical significance for this procedure ( p = 0.063) [ 22 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.